Oncolytic Virus Therapy is an exciting, increasingly recognized discipline in cancer research. Although the connection between viruses and cancer regression was recognized in the early 20th century, it wasn't until the recent development of advanced genetic engineering techniques that true progress has been made using virotherapy to attack and destroy cancer cells. Today, researchers can modify existing viruses to create new oncolytic viruses that are less susceptible to immune suppression while more specifically targeting particular classes of cancer cells. Additionally, these modified oncolytic viruses can be adapted to insert and express cancer-suppressing genes and diagnostic proteins.
Oncolytic Virus Therapy is an exciting, increasingly recognized discipline in cancer research. Although the connection between viruses and cancer regression was recognized in the early 20th century, it wasn't until the recent development of advanced genetic engineering techniques that true progress has been made using virotherapy to attack and destroy cancer cells. Today, researchers can modify existing viruses to create new oncolytic viruses that are less susceptible to immune suppression while more specifically targeting particular classes of cancer cells. Additionally, these modified oncolytic viruses can be adapted to insert and express cancer-suppressing genes and diagnostic proteins.
The application of oncolytic virus therapy includes melanoma, prostate cancer, breast cancer, ovarian cancer and others, and the proportion of R&D Investment for melanoma in 2017 is about 34%.
Market competition is intense. Amgen, Oncolytics Biotech, Viralytics, Transgene SA are the leading developers in the industry: with high investment in research marketing and they will monopoly position in the industry.

According to this study, over the next five years the Oncolytic Virus Therapy market will register a 25.8% CAGR in terms of revenue, the global market size will reach US$ 10 million by 2024, from US$ 2 million in 2019. In particular, this report presents the global revenue market share of key companies in Oncolytic Virus Therapy business, shared in Chapter 3.

This report presents a comprehensive overview, market shares and growth opportunities of Oncolytic Virus Therapy market by product type, application, key companies and key regions.

This study considers the Oncolytic Virus Therapy value generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2014 to 2019 in Section 2.3: and forecast to 2024 in section 10.7.
HSV-based Oncolytic Viruses
Adenoviruses-based Oncolytic Viruses
Vesicular Stomatitis Virus-based Oncolytic Viruses
Newcastle Disease Virus-based Oncolytic Viruses
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4: and forecast to 2024 in section 10.8.
Melanoma
Prostate?Cancer
Breast?Cancer
Ovarian?Cancer?
Others

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Amgen
Oncolytics Biotech
Viralytics
Transgene SA
Oncolys BioPharma
Targovax
PsiOxus Therapeutics
SillaJen?Biotherapeutics
Sorrento Therapeutics
Lokon Pharma
Genelux Corporation
Vyriad
TILT Biotherapeutics
Cold Genesys

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Oncolytic Virus Therapy market size by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Oncolytic Virus Therapy market by identifying its various subsegments.
Focuses on the key global Oncolytic Virus Therapy players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Oncolytic Virus Therapy with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the size of Oncolytic Virus Therapy submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.